drugset / Trial / NCT05283109
ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM
Phase 1
Active not recruiting
24 enrolled
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1b study of P30-linked EphA2, CMV pp65, and survivin vaccination (collectively called the P30-EPS vaccine) in HLA-A\*0201 positive patients with a newly diagnosed, unmethylated, and untreated World Health Organization (WHO) grade IV malignant glioma.
Timeline
- Start
- 2023-08-30
- Primary completion
- 2025-04-11
- Completion
- 2028-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | P30-EPS | Vaccine | 200 ug | — |
| Subject | P30-EPS | Vaccine | 300 ug | — |
| Subject | P30-EPS | Vaccine | 400 ug | — |
| Background | Hiltonol | Other / unclassified | 20 ug/kg | Other |